{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T22:26:51Z","timestamp":1747175211341,"version":"3.40.5"},"reference-count":89,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1053\/j.seminhematol.2024.07.002","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T16:05:47Z","timestamp":1720281947000},"page":"306-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma"],"prefix":"10.1053","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10297","key":"10.1053\/j.seminhematol.2024.07.002_bib0001","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.07.002_bib0002","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2024.07.002_bib0003","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.02232","article-title":"Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.07.002_bib0004","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.07.002_bib0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.07.002_bib0006","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.07.002_bib0007","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3324\/haematol.2022.282510","article-title":"Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients","volume":"108","author":"Gagelmann","year":"2023","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.07.002_bib0008","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.07.002_bib0009","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/1078-0432.CCR-23-3759","article-title":"biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma","volume":"30","author":"Oliver-Caldes","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.002_bib0010","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.19227","article-title":"Bridging treatment prior to chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"204","author":"Bal","year":"2024","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.07.002_bib0011","doi-asserted-by":"crossref","first-page":"504.e1","DOI":"10.1016\/j.jtct.2023.05.016","article-title":"Intensity of cyclophosphamide-based bridging therapy before chimeric antigen receptor T cell therapy in myeloma","volume":"29","author":"Zafar","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.002_bib0012","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41408-024-00993-0","article-title":"Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium","volume":"14","author":"Afrough","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.07.002_bib0013","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.2023021221","article-title":"CAR T-cell therapy in multiple myeloma: mission accomplished?","volume":"143","author":"Rasche","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.002_bib0014","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","article-title":"Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma","volume":"38","author":"Fischer","year":"2024","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.07.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-024-00763-8","article-title":"Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma","author":"Rade","year":"2024","journal-title":"Nat Cancer"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.07.002_bib0016","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Via","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.07.002_bib0017","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1053\/j.seminhematol.2024.07.002_bib0018","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.07.002_bib0019","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1002\/j.1460-2075.1992.tb05482.x","article-title":"A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma","volume":"11","author":"Laabi","year":"1992","journal-title":"EMBO J"},{"key":"10.1053\/j.seminhematol.2024.07.002_bib0020","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","author":"Firestone","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.07.002_bib0021","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/s41375-020-0930-x","article-title":"Development of CAR-T cell therapies for multiple myeloma","volume":"34","author":"Gagelmann","year":"2020","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.07.002_bib0022","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.283058","article-title":"Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible","author":"Engelhardt","year":"2024","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.002_bib0023","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"Fernandez de Larrea","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.07.002_bib0024","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"issue":"485","key":"10.1053\/j.seminhematol.2024.07.002_bib0025","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.seminhematol.2024.07.002_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2024.05.003","article-title":"Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab","author":"Chari","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.002_bib0027","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/S2352-3026(22)00385-4","article-title":"GPRC5D-targeting chimeric antigen receptors: a new treatment for multiple myeloma?","volume":"10","author":"Gagelmann","year":"2023","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.002_bib0028","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.07.002_bib0029","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T Cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.07.002_bib0030","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase \u2161 trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.07.002_bib0031","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.07.002_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.654839","article-title":"SLAM associated protein signaling in T cells: tilting the balance toward autoimmunity","volume":"12","author":"Gartshteyn","year":"2021","journal-title":"Front Immunol"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.07.002_bib0033","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.07.002_bib0034","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.002_bib0035","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol Ther"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.002_bib0036","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41591-022-02195-2","article-title":"Off-the-shelf CAR T cells for multiple myeloma","volume":"29","author":"Brudno","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.002_bib0037","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat Commun"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.07.002_bib0038","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free sleeping beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Ther"},{"key":"10.1053\/j.seminhematol.2024.07.002_bib0039","unstructured":"Danhof S, Prommersberger S, Beckmann J, et al. Safety and feasibility of SLAMF7 CAR-T cells in multiple myeloma. EBMT-EHA 6th CAR-T Meeting 2024:BA1-1."},{"issue":"6","key":"10.1053\/j.seminhematol.2024.07.002_bib0040","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/s41375-022-01559-4","article-title":"CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells","volume":"36","author":"O'Neal","year":"2022","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.07.002_bib0041","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2022-157950","article-title":"Preclinical activity of allogeneic CS1-specific CAR T-cells (UCARTCS1) in multiple myeloma","volume":"140","author":"Korst","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.07.002_bib0042","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clim.2018.10.006","article-title":"The role of surface molecule CD229 in multiple myeloma","volume":"204","author":"Olson","year":"2019","journal-title":"Clin Immunol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.07.002_bib0043","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3324\/haematol.2010.036814","article-title":"Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma","volume":"96","author":"Atanackovic","year":"2011","journal-title":"Haematologica"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.07.002_bib0044","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.4049\/jimmunol.174.10.5977","article-title":"Identification of Grb2 as a novel binding partner of the signaling lymphocytic activation molecule-associated protein binding receptor CD229","volume":"174","author":"Martin","year":"2005","journal-title":"J Immunol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.07.002_bib0045","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1080\/21645515.2015.1046658","article-title":"CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma","volume":"11","author":"Yousef","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"705","key":"10.1053\/j.seminhematol.2024.07.002_bib0046","doi-asserted-by":"crossref","first-page":"eadd7900","DOI":"10.1126\/scitranslmed.add7900","article-title":"Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity","volume":"15","author":"Vander Mause","year":"2023","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.07.002_bib0047","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/s41375-022-01585-2","article-title":"Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion","volume":"36","author":"Olson","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.07.002_bib0048","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.002_bib0049","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.07.002_bib0050","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(24)00070-X","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial","author":"O'Donnell","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2024.07.002_bib0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14712598.2024.2357382","article-title":"Anti-CD38 monoclonal antibodies in multiple myeloma with gain\/amplification of chromosome arm 1q: a review of the literature","volume":"24","author":"Barbieri","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.07.002_bib0052","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","article-title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials","volume":"7","author":"Usmani","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.07.002_bib0053","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.07.002_bib0054","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1021\/acs.molpharmaceut.8b00584","article-title":"Anti-multiple myeloma activity of nanobody-based anti-CD38 chimeric antigen receptor T cells","volume":"15","author":"An","year":"2018","journal-title":"Mol Pharm"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.07.002_bib0055","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","article-title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","volume":"7","author":"Glisovic-Aplenc","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.07.002_bib0056","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.3324\/haematol.2020.276402","article-title":"European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma","volume":"106","author":"Bruno","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.002_bib0057","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1959102","article-title":"Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma","volume":"10","author":"Feng","year":"2021","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.002_bib0058","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.002_bib0059","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.07.002_bib0060","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2326-6066.CIR-23-0839","article-title":"Dual chimeric antigen receptor T cells targeting CD38 and SLAMF7 with independent signaling demonstrate preclinical efficacy and safety in multiple myeloma","volume":"12","author":"Roders","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.07.002_bib0061","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol Ther"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.07.002_bib0062","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.002_bib0063","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1189\/jlb.0211096","article-title":"Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes","volume":"91","author":"Dement-Brown","year":"2012","journal-title":"J Leukoc Biol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.002_bib0064","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.07.002_bib0065","first-page":"569","article-title":"CD21 and FCRL5 form a receptor complex with robust B-cell activating capacity","volume":"30","author":"Franco","year":"2018","journal-title":"Int Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.002_bib0066","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/hematology.2023000433","article-title":"Current use of bispecific antibodies to treat multiple myeloma","volume":"2023","author":"Lee","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.002_bib0067","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-023-01702-2","article-title":"Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma","volume":"9","author":"Yu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.002_bib0068","doi-asserted-by":"crossref","first-page":"e20192203","DOI":"10.1084\/jem.20192203","article-title":"Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression","volume":"218","author":"Lanitis","year":"2021","journal-title":"J Exp Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.07.002_bib0069","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41417-023-00709-9","article-title":"Enhancing CAR-T cells: unleashing lasting impact potential with phytohemagglutinin activation in in vivo leukemia model","volume":"31","author":"Sert","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.07.002_bib0070","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-cell therapy for multiple myeloma: state of the art and prospects","volume":"8","author":"van de Donk","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.002_bib0071","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","article-title":"Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient?","volume":"15","author":"Kegyes","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.002_bib0072","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.002_bib0073","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat Commun"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.07.002_bib0074","article-title":"Updated results of a phase I, open-label study of BCMA\/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Du","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.07.002_bib0075","article-title":"Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed\/refractory multiple myeloma: a systematic review and meta-analysis","volume":"14","author":"Xu","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.002_bib0076","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.002_bib0077","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.07.002_bib0078","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/10428194.2022.2030476","article-title":"A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma","volume":"63","author":"Zhang","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.07.002_bib0079","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.07.002_bib0080","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.07.002_bib0081","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.07.002_bib0082","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.002_bib0083","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.07.002_bib0084","first-page":"1521","article-title":"CD28, a marker associated with tumoral expansion in multiple myeloma","volume":"4","author":"Robillard","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.07.002_bib0085","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/neuonc\/noy045","article-title":"Comment on \u201ctrivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.\u201d","volume":"20","author":"Caruso","year":"2018","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.07.002_bib0086","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/2767-9764.CRC-23-0434","article-title":"Ex vivo efficacy of SAR442257 anti-CD38 trispecific T-cell engager in multiple myeloma relapsed after daratumumab and BCMA-targeted therapies","volume":"4","author":"Keller","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.07.002_bib0087","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/CCO.0000000000000983","article-title":"T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA","volume":"35","author":"van de Donk","year":"2023","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.07.002_bib0088","doi-asserted-by":"crossref","first-page":"e786","DOI":"10.1016\/S2352-3026(22)00226-5","article-title":"Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper","volume":"9","author":"Gagelmann","year":"2022","journal-title":"Lancet Haematol"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.07.002_bib0089","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence","volume":"124","author":"Barlogie","year":"2014","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T17:39:42Z","timestamp":1729013982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0037196324000842"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.07.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}